CRISPR Therapeutics AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $15.6 Mil. CRISPR Therapeutics AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $223.0 Mil. CRISPR Therapeutics AG's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,882.8 Mil.
CRISPR Therapeutics AG's debt to equity for the quarter that ended in Dec. 2023 was 0.13.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for CRISPR Therapeutics AG's Debt-to-Equity or its related term are showing as below:
CRSP'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.32 Med: 0.08 Max: 0.13
Current: 0.13
During the past 10 years, the highest Debt-to-Equity Ratio of CRISPR Therapeutics AG was 0.13. The lowest was -1.32. And the median was 0.08.
CRISPR Therapeutics AG Debt-to-Equity Historical Data
The historical data trend for CRISPR Therapeutics AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
CRISPR Therapeutics AG Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
0.06 |
0.04 |
0.09 |
0.13 |
0.13 |
|
CRISPR Therapeutics AG Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.13 |
0.13 |
0.14 |
0.14 |
0.13 |
Competitive Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's Debt-to-Equity falls into.
CRISPR Therapeutics AG Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
CRISPR Therapeutics AG's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
CRISPR Therapeutics AG's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (CRISPR Therapeutics AG) Business Description
Traded in Other Exchanges
Address
Baarerstrasse 14, Zug, CHE, CH-6300
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Executives
| Samarth Kulkarni |
officer: Chief Business Officer |
C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139 |
| Raju Prasad |
officer: Chief Financial Officer |
CRISPR THERAPEUTICS, INC., 105 W FIRST STREET, BOSTON MA 02127 |
| Phuong Khanh Morrow |
officer: Chief Medical Officer |
C/O CRISPR THERAPEUTICS, 610 MAIN STREET, CAMBRIDGE MA 02139 |
| Maria Fardis |
director |
C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
| Brendan Smith |
officer: Chief Financial Officer |
29 HARTWELL AVENUE, LEXINGTON MA 02421 |
| Michael John Tomsicek |
officer: Chief Financial Officer |
28 OVERLOOK DRIVE, BEDFORD MA 01730 |
| Bolzon Bradley J Phd |
director |
ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
| Rodger Novak |
director, officer: Chief Executive Officer |
C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139 |
| Harold Edward Fleming |
director |
C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139 |
| Lawrence Otto Klein |
officer: Chief Business Officer |
C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET 7TH FLOOR, CAMBRIDGE MA 02139 |
| James R. Kasinger |
officer: General Counsel and Secretary |
C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE MA 02139 |
| Tony W Ho |
officer: See Remarks |
CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139 |
| Douglas A Treco |
director |
87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140 |
| Pablo J Cagnoni |
director |
ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
| Katherine A High |
director |
3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104 |
CRISPR Therapeutics AG (CRISPR Therapeutics AG) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRSP has been successfully added to your